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Abstract Thymidine kinase (TK1) is an enzyme involved in
DNA synthesis that leaks into the blood as a result of high cell
turnover, particularly in the case of cancer. Serum TK1 activ-
ity has been used for prognosis and monitoring of leukemia
and lymphoma patients for many years. Here, we describe the
first clinical results with the newly developed TK 210 ELISA
from AroCell AB. Sera from 124 breast cancer patients with
known TNM classification along with sera from 53 healthy
females were analyzed by TK 210 ELISA for TK1 protein and
TK1 activity levels by the 3[H]-deoxythymidine (dThd) phos-
phorylation assay. The limit of detection for the TK 210
ELISA was 0.17 ng/ml, and 60 % of the sera from female
blood donors were below this value. The median TK1 levels
found in sera from breast cancer patients with T1 to T4 stage
disease were 0.31, 0.46, 0.47, and 0.55 ng/ml, and these levels
significantly differed from healthy controls. The median values
of the biomarker CA 15-3 were also increased in patient sera
from T1 to T4 patients (16, 34, 36, 40 U/ml, respectively). TK
210 ELISA showed significantly higher sensitivity for the T1
and T2 breast cancer patients compared to the TK activity assay.
The combination of the TK1 ELISA and CA 15-3 biomarkers
demonstrated a significant increase in sensitivity up to 15 %
compared to each marker alone. This evaluation of the TK
210 ELISA strongly suggests that it can provide independent
and complementary information for patients with breast cancer.
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Introduction
Breast cancer is one of the most common forms of cancer that
accounts for 10–18 % of all cancer deaths in women [1]. Pre-
operative chemotherapy in combination with radiation or hor-
monal therapy has increased the efficiency of breast cancer
treatment [2, 3]. Still, the anti-cancer therapy is not very ef-
fective especially in the case of patients with metastatic dis-
ease. Tumor biomarkers are the substances that indicate the
presence of cancer and play an important role in patient man-
agement. Serum biomarkers are potentially useful for early
diagnosis, therapy monitoring, and predicting tumor relapse
[4]. Several biomarkers such as estrogen receptor (ER) [5],
human epidermal growth factor receptor 2 (HER-2/neu)
[6], carbohydrate antigen 15-3 (CA 15-3) [7], and
carcinoembryonic antigen (CEA) [8] have been evaluated for
prognosis, diagnosis, and treatment monitoring in breast cancer.
Out of these, CA 15-3 is themost commonly used. It is a protein
product of the MUC-1 gene, which is shed into the blood
stream in an under glycosylated form from adenocarcinomas
[9]. According to the ASCO 2015 guidelines, CA 15-3 and
CEA can be used for monitoring the response to therapy only
together with physical examination and imaging. The relatively
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low sensitivity and poor specificity of CA 15-3 for early stage
tumors limits its use. So there is a need for biomarkers that can
fulfil the dual purpose of detecting the tumors at early stages of
progression and monitoring treatment response.
Thymidine kinase 1 (TK1) is another interesting serum
biomarker that has been used for prognosis and monitoring
therapy in leukemia and lymphoma patients during the last
two decades [10–13]. TK1 is an ATP dependent enzyme in-
volved in synthesis of pyrimidine deoxy nucleotides via the
salvage pathway. The protein and activity levels of TK1 are
cell cycle regulated and both increase in late G1/early S phase
and reach a peak in late S/early G2 phase. Finally the TK1
protein is degraded by a specific mechanism in M-phase
[14–17]. Currently, different assays are used to measure serum
TK1 activity including the TK-REA, TK-Liaison, Divitum,
and 3[H]-dThd phosphorylation assays. Studies have shown
that these assays are clinically valuable for prognosis and mon-
itoring therapy particularly in lymphoma and leukemia diseases
[11–13]. Development of antibodies against different regions
of TK1 to determine TK1 protein levels provided an alternative
to TK1 activity assay [18, 19]. Several clinical studies with an
antibody based dot blot assay demonstrated that TK1 protein
assays have higher sensitivity than the TK1 activity assays in
patients with solid tumors [20–23]. Another immunoaffinity
assay has been described recently, and it showed similar results
to other TK1 protein assays with breast and prostate cancer
samples. Furthermore, differences in the molecular forms of
serum TK1 in patients with different types of tumors could be
identified [24]. However, these assays are not compatible with
routine clinical use. Several attempts have been made to devel-
op an ELISA test for serum TK1 quantification [25–27] but so
far none of them are commercially available for clinical use.
Therefore there is a need to develop a TK1 ELISA with a
detection limit in the range of nanograms per milliliter.
Here we evaluate the performance of the new sandwich TK
210 ELISA produced by AroCell AB, Uppsala, Sweden,
which is based on two monoclonal antibodies raised against
the C-terminal region of the TK1 protein. The results were
obtained with clinical samples from breast cancer patients with
known TNM staging as well as CA 15-3 levels. The same
samples were analyzed with TK 210 ELISA and TK1 activity
assay [24, 28]. The TK 210 ELISA appears to offer many
advantages such as elimination of radioactive materials, easily
performed in clinical chemistry laboratories, and a capacity to
detect early stage breast cancer disease.
Materials and methods
Serum samples
Sera from healthy females (N=53) were collected at the Blood
Transfusion Centre in Ljubljana, pre-treatment breast cancer
sera (N=76) were collected at the Institute of Oncology at
Ljubljana, processed and stored at −20 °C until they were
analyzed for CA 15-3 at the University Medical Centre
Ljubljana as well as for TK1 activity (3[H]-dThd phosphory-
lation assay) and TK1 protein at the Swedish University of
Agricultural Sciences, Uppsala. The project was approved by
the Slovenian Medical Ethics committee (KME 83/04/08).
Another set of breast cancer sera (N=48) were purchased from
Biotheme Research Solutions Inc., FL, USA. These samples
were collected as de-identified diagnostic remainders exempt
fromTitle 46, Title 21, and HIPAA IRB/Consent requirements.
The serum samples were collected under an IRB-approved
protocol or collected as consented donor samples from
FDA-licensed/registered facility following GMPs. The
mean and median age of healthy individuals was 44 years
(range 22–63 years) and 62 years (range 30–92) in the
case of breast cancer patients. Tumor staging was performed
according to tumor size, lymph nodes, and metastasis (TNM)
classification by AJCC.
3[H]-dThd phosphorylation assay
The TK1 activity in serum samples was determined by using
an optimized 3[H]-dThd phosphorylation assay as described
previously [24, 28]. In brief, 10 μl of serum sample was
incubated with a reaction buffer containing 20 mM Tris/
HCl, pH 7.6, 2 mM dithiothreitol, 5 mM NaF, 5 mM MgCl2,
5 mM ATP, and 5 μM of dThd at 37 °C for 1 h. Then 10 μl
was applied on DE-81 filter paper (Whatman). The unbound
substrate was removed by ammonium formate wash, and the
products were eluted and the radioactivity was measured by
scintillation counting [28]. TK1 activity is expressed as
picomolar dTMP formed per minute and milliliter serum.
The sandwich TK 210 ELISA procedure
TK1 protein levels in serum samples were determined using
the TK 210 ELISA, following the manufacturer’s instruc-
tions (www.arocell.com). The following procedure was
performed. (1) Serum samples, controls, and calibrators
were pre-incubated with the sample dilution buffer for
1 h at room temperature. (2) An antibody coated 96-well
plate in the kit was pre-washed 4 times with wash buffer
using a Tecan Hydroflex washer before adding the incubat-
ed samples and calibrators. (3) After a pre-wash, 100 μl of
calibrators, controls, and serum samples were added to each
well, and the plate was incubated for 2 h on a rocking
platform. (4) After non-binding molecules were washed
away during 4×2 min with the wash buffer, 100 μl of
biotin-labelled anti-TK1 antibody was applied to each well
followed by incubation for 1 h. (5) Then, the plate was
washed again 4 times and incubated with the streptavidin-
HRP solution (100 μl per well) for 30 min. (6) A final
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wash with wash buffer 4 times to remove unbound HRP
was done. (7) The wells were subsequently incubated for
15 min with the TMB solution. The reactions were stopped
by adding 2 N HCL, and the absorbance in each well was
determined using a microplate reader set to 450 nm (reference
wave length 540 nm). Serum TK1 protein levels were deter-
mined using the calibrator curve from each plate and the 4-PL
curve fit program. All measurements with serum samples were
done in duplicates. The limit of detection (LOD), cut-off value
for healthy, and the overall coefficient of variation (CV) were
determined. The TK1 protein concentration (ng/ml) in each
patient was calculated after adding the LOD value, i.e.,
0.17 ng/ml to all values.
The CA 15-3 analysis
Breast cancer sera from different stages were analyzed for
CA15-3 using a commercial chemiluminescence assay for
the Liaison analyzer (DiaSorin) as described in the product
instructions. The cut-off value (29 U/ml) was estimated based
on CA 15-3 levels in sera from healthy females (N=53).
The TK-Liaison assay
Sera from healthy females (N=53) and breast cancer (N=76)
were also analyzed using the commercially available
TK-Liaison assay according to the manufacture’s in-
structions (www.DiaSorin.com) in order to determine
the correlation with the 3[H]-deoxythymidine (dThd)
phosphorylation assay.
Statistical analysis
The TK1 activity and TK1 protein distribution in sera from
healthy and breast cancer patients were tested for normality
using the D’Agostino and Pearson omnibus normality test.
The TK1 activity and protein levels in healthy as well as in
breast cancer patients showed non-Gaussian distribution. The
spearman correlation coefficient (rs) was used to determine
the correlation between TK1 activities and TK1 protein levels.
STK1 activity, TK1 protein levels, and CA 15-3 values in
different sub groups were log transformed (log10) before anal-
ysis. The Mann–Whitney t test was used to evaluate the dif-
ference between the groups. The Kurskal–Wallis test was per-
formed to distinguish more than two groups. For sensitivity
and specificity analysis and for comparison of assays, receiver
operating characteristic (ROC) curves were constructed.
Statistical analyses were performed using the Graph Pad
Prism 5.0 (Graph Pad Software, La Jolla, CA, USA). The
level of significance was set at P<0.05.
Results
Serum samples from 53 healthy individuals and 124 breast can-
cer patients were analyzed for serum TK1 activity and TK1
protein levels, as described in the BMaterials and methods^ sec-
tion. The LOD was 0.17 ng/ml, and within-run CVs were less
than <10 % for the TK 210 ELISA. CV between the runs was
<20 %, and in studies of recovery and linearity on dilution-
measured values ranged from 91 to 105 % of expected at con-
centrations of 0.22–22 ng/ml. In healthy, TK1 activity values
ranged from 0.6 to 3.1 pmol/min/ml (mean±SD=1.6±0.6)
and in breast cancer patients, the STK1 activity levels were sig-
nificantly higher compared to the healthy group (Fig. 1a), in the
range of 0.9 to 48 pmol/min/ml (mean±SD=4.5±8.3) with a
median value of 2.5 pmol/min/ml.Many of the sera from healthy
persons had TK1 protein levels at or below the detection limit
(0.17 ng/ml) and 40%of them had detectable TK1 protein levels
in the range of 0.17 to 0.33 ng/ml (the estimated mean
±SD=0.2±0.05 using the LOD value for those below this val-
ue). Significantly higher serumTK1 protein levels were found in
sera from breast cancer patients compared to healthy, and the
protein concentration ranged from 0.17 to 9.9 ng/ml (mean
±SD=1.0±1.9) (Fig. 1b). TK1 activity and TK1 protein levels
in healthy as well as breast cancer patients did not show any
significant correlation with the age of the individuals (P=0.51,
P=0.41, P=0.56, P=0.44). However, significant correlations
were found between the serum TK1 activity and TK1 protein
levels in healthy (rs=0.72, P<0.0001) and breast cancer pa-
tients (rs=0.60, P<0.0001). Overall, TK-Liaison assay had sig-
nificant correlation with the 3[H]-dThd phosphorylation assay
(rs = 0.75, P < 0.0001) as well as with TK 210 ELISA
(rs=0.58, P<0.0001).
TK1 activity, TK1 protein, and CA 15-3 levels in sera
from patients with breast cancer
The performance of the TK1 activity assay, TK 210 ELISA,
and CA 15-3 with sera from patients with all stages of breast
cancer were evaluated by constructing ROC curves. The re-
sults of these analyses are shown in Table 1 and Fig. 1. The
TK1 activity assay showed an area under the curve (AUC) of
0.79 using a cut-off value of 3.0 pmol/min/ml, the sensitivity
was 0.26, and the specificity of 0.96 (Fig. 1c). The TK 210
ELISA, however, had an AUC of 0.90, P<0.0001, and at a
cut-off value of 0.32 ng/ml, the sensitivity obtained was 0.50
and the specificity 0.98 (Table 1) (Fig. 1d). The CA 15-3
values in the breast cancer sera showed a broad range from
6 to 716 U/ml with a median of 24 U/ml (mean±SD=67
±115). Further analysis compared the CA 15-3 and serum
TK1 activity and protein values; a significant correlation
was found between CA 15-3 and TK1 protein levels
(rs=0.33, P=0.0022) for the entire breast cancer group but
this was not observed with TK1 activity levels (P=0.14).
Tumor Biol. (2016) 37:11937–11945 11939
TK1 activity, protein, and CA 15-3 levels in relation to T1
to T4 stage
The median TK1 activity values were somewhat higher in
T1 (2.2 pmol/min/ml) compared to T4 stage disease
(2.8 pmol/min/ml), however, the TK1 activity levels in sera
from patients at all these stages significantly differ from those
in healthy individuals (Fig. 2a). The TK1 protein levels in-
creased more clearly but overall followed a similar pattern with
regard to tumor stage. The median values were 0.33 and
0.55 ng/ml in T1 and T4 patients, respectively (Fig. 2b).
Furthermore, no correlations were found between TK1 activity,
TK1 protein, and CA 15-3 values in T1 patients. The ROC
curves for TK1 activity in T1 patients showed an AUC of
Fig. 1 TK1 activity and protein
levels in sera from healthy and
from the entire breast cancer
groups. a Log TK1 activity levels
in sera from breast patients and
healthy individuals. b Log TK1
protein levels in sera from healthy
and breast cancer patients. Error
bars denote maximum and
minimum values. The receiver
operating characteristic (ROC)
curves c TK1 activity assay. d
TK 210 ELISA for breast cancer
patients in comparison with
healthy individuals
Table 1 Results from the ROC
curve analysis with the different
assays
Group AUC Sensitivity [95 % CI] Specificity [95 % CI]
Breast cancer vs healthy
TK1 activity assay 0.79 0.26 [0.19–0.35] 0.96 [0.89–0.97]
TK 210 ELISA 0.90 0.50 [0.42–0.59] 0.98 [0.89–0.99]
T1 vs healthy
TK1 activity assay 0.76 0.14 [0.05–0.30] 0.96 [0.86–0.97]
TK 210 ELISA 0.88 0.34 [0.19–0.52] 0.98 [0.89–0.99]
CA 15-3 0.65 0.20 [0.08–0.36] 0.98 [0.89–0.99]
TK 210 ELISA + CA15-3 0.76 0.40 [0.32–0.56] 0.98 [0.89–0.99]
T2 vs healthy
TK1 activity assay 0.86 0.39 [0.26–0.53] 0.96 [0.86–0.97]
TK 210 ELISA 0.92 0.61 [0.49–0.71] 0.98 [0.88–0.99]
CA 15-3 0.82 0.63 [0.48–0.75] 0.98 [0.89–0.99]
TK 210 ELISA + CA15-3 0.94 0.76 [0.64–0.84] 0.98 [0.89–0.99]
Cut-off values for TK1 activity assay is >3.0 pmol/min/ml, for TK 210 ELISA is >0.32 ng/ml, and for CA 15-3
>29 U/ml to determine the sensitivity and specificity
AUC area under curve, CI confidence interval
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0.76 (Fig. 2c), the sensitivity was 0.14 with a specificity of 0.96
(Table 1), while the TK 210 ELISA showed a significantly
higher AUC (0.88) as well as a sensitivity of 0.34 and a spec-
ificity of 0.98 (Fig. 2d). CA 15-3 demonstrated slightly higher
sensitivity compared to the TK1 activity assay, but it was less
than TK1 ELISA (Table 1). These results indicate that TK1
ELISA can detect early stage breast cancer better than the
TK1 activity and CA 15-3 assays.
In T2 patients, TK1 activity, TK 210 ELISA, and CA 15-3
levels were significantly higher compared to those in T1 pa-
tients (Table 2) (Fig. 3). Furthermore, TK1 activity and TK
protein levels were increased in patients with lymph node
involvement andmetastatic disease compared to those without
such complications (Fig. 3a–d). In the case of CA 15-3, only
metastatic patients had significantly higher CA 15-3 levels
(Fig. 3e, f, Table 2). We also found significant correlations
between the three assays, i.e., TK1 activity and TK 210
ELISA (r= 0.65, P< 0.0001), TK1 activity and CA 15-3
(r= 0.41, P= 0.0028), and TK 210 ELISA and CA 15-3
(r=0.46, P=0.0005).
In ROC curve analysis, the TK 210 ELISA as well as CA
15-3 (Fig. 4a, b) showed superior sensitivity compared to TK1
activity assay (Fig. 4c) in patients with T2 stage breast cancer.
However, the combination of TK 210 ELISA and CA 15-3
increased the sensitivity significantly from 0.6 to 0.76 and the
AUC from 0.92 to 0.94 (Table 1, supplement Fig 1). These
results strongly indicate that the two assays can complement
each other, thereby increasing the clinical usefulness of these
assays. In 41 out of 124 patients with known histological
grading (DCIS, ID/L, and IDC), the DCIS and ID/L patients
apparently show higher serum TK1 protein as well as CA 15-3
levels compared to the other types (Table 2). Taken together,
these results indicate that TK 210 ELISA should be a valuable
complement to the in vitro diagnostic procedures applied for
breast cancer patients.
Discussion
Proliferation in tumor cells correlates with high levels of TK1
since this enzyme plays an important role in pyrimidine
deoxynucleotide synthesis. Because of this characteristic,
TK1 has been used as a proliferation marker in lymphomas
and leukemias in human medicine for many years [10–12].
Several commercial assays are available to measure the TK1
activity levels in different malignancies, such as e.g., TK-
REA, TK-Liaison, and Divitum [10, 29, 30]. Even though
TK1 activity levels show a correlation with the stage of breast
cancer disease, the overall sensitivity of the assays is rather
low i.e., less than 35 % [30–32]. This limits the clinical use of
TK1 activity assays in breast cancer patients.
Development of antibodies against the C-terminal region of
TK1 provides an alternative way to determine TK1, and in this
case, it is the TK1 protein levels that are measured [18].
Fig. 2 TK1 activity and protein
levels in breast cancer sera based
on stage (T1–T4). a Log TK1
activity levels in sera from breast
cancer patients based on T stage
(T1–T4) and healthy individuals.
b Log TK 210 ELISA in sera
from healthy and breast cancer
patients (T1–T4). Error bars
denote maximum and minimum
values. The ROC curveanalysis
for c TK1 activity assay. d TK
210 ELISA for T1 breast cancer
patients in comparison with
healthy individuals
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Previous studies with a dot blot assay showed that when the
TK1 protein levels were determined they were significantly
higher in sera from patients with many different types of solid
tumors [20, 21]. A recent study with an immunoaffinity assay
demonstrated that TK1 protein levels are significantly in-
creased in sera from patients with early stage breast and pros-
tate tumor disease, while the TK1 activity was not. A reason
for this could be that there was a larger proportion of inactive
TK1 in serum from patients with solid tumors compared to
those seen in sera from leukemia patients [24]. Therefore the
development of an ELISA based assay, which could deter-
mine both the active and inactive TK1 protein in sera from
cancer patients should be a great advantage in in-vitro
diagnostics.
The first clinical study with commercial TK1 (AroCell AB,
Uppsala, Sweden) sandwich ELISA was published in 2009
with a combination of monoclonal and polyclonal antibody
made against peptides from the C-terminal region of TK1
[33]. However, this ELISA had relatively low sensitivity and
specificity and relied on polyclonal antibodies, making robust
production of the test complicated. The new version of TK
210 ELISA from AroCell AB has been developed based on
two monoclonal antibodies. It can overcome the problems
with polyclonal antibodies, but it also increases the sensitivity
of the assay as demonstrated in this study. Some earlier studies
with other TK1 ELISA assays have been published [25, 26]
but the details about the antibodies are not reported. An
attempt to develop a direct ELISA based on one monoclonal
antibody for detection of early stage lung cancer has been
published [27]. However, the levels of serum TK1 reported
are several orders higher than those described here and the
commercial availability of this assay is unknown [27].
To the best of our knowledge, this study is the first to
demonstrate the performance of a fully developed TK 210
ELISA, which is commercially available. The results re-
ported here strongly suggest that the TK 210 ELISA is
able to detect a significant differences in the levels of the
TK1 protein in sera from breast cancer patients in the T1,
T2, and T3 stages compared to healthy. The results with
the TK activity assay gave over all similar results, and
there was a correlation between the two assays, but the
sensitivity of the activity assay was approximately half of
the TK 210 ELISA. Significant differences were observed
between the serum TK1 levels in the group of patients with
lymph node involvement and metastatic disease compared
to those without, suggesting that the TK 210 ELISA can be
used for prognosis as well as monitoring of breast cancer
both in early and later stages of the disease.
Several studies have been done to determine the clinical
value of CA 15-3 as a biomarker in breast cancer. CA 15-3
has low sensitivity (10 %) for detection of early stage tumors
[34], but is widely used for monitoring therapy of patients
with advanced stages of breast cancer [35, 36]. The overall
sensitivity of CA 15-3 assay for breast cancer is in the range
Table 2 Fraction of breast cancer
patients with positive TK1
activity, TK 210 ELISA, and CA
15-3 values in relation to clinical
and pathologic parameters
Parameter No. of patients TK1 activity (pmol/min/ml) TK1 ELISA (ng/ml) CA 15-3 (U/ml)
Patient no. (% >3.0) Patient no. (% >0.32) Patient no. (% >29)
Stage
T1 35 5 (14) 12 (34) 7 (20)
T2 54 22 (40) 33 (61) 34 (63)
T3 12 5 (38) 8 (67) 7 (58)
T4 4 2 (50) 2 (50) 3 (75)
Subsets in T1
LN− 23 5 (21.7) 8 (34.7) 3 (13)
LN+ 12 1 (8.25) 4 (33.3) 4 (33)
M− 32 5 (15.6) 10 (31.2) 6 (19)
M+ 3 1 (33.3) 2 (66.7) 2 (66.7)
Subsets in T2
LN− 24 8 (30) 14 (58.3) 15 (62.5)
LN+ 30 14 (46.6) 21 (70) 18 (60)
M− 23 7 (24.1) 13 (44.8) 8 (34.7)
M+ 27 13 (48.1) 20 (74) 24 (88)
Histological grade
DCIS 6 1 (16.6) 5 (83.3) 5 (83.3)
ID/L 9 6 (66.6) 7 (77.7) 8 (88.8)
IDC 26 11 (38.4) 18 (69.2) 20 (74)
T tumor size, LN lymph node involvement,M systemic metastasis, DCIS ductal in situ carcinoma, ID/L invasive
ductal/ lobular carcinoma, IDC invasive ductal carcinoma
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Fig. 4 ROC curve analysis for a
STK 210 ELISA levels, b CA 15-
3 levels, and c STK1 assays with
T2 breast cancer patients and
healthy individuals
Fig. 3 TK1 activity, TK 210 ELISA, and CA 15-3 values in T2 patients.
a Log TK1 activity levels in T2 patients with lymph node involvement
(N1 + N2) without nodal involvement (N0). b Log TK1 activity levels in
T2 patients with metastasis (M1 + M2) without metastasis (M0). c Log
TK 210 ELISAvalues in T2 patients with lymph node involvement (N1 +
N2) without nodal involvement (N0). d Log TK 210 ELISAvalues in T2
patients with metastasis (M1 + M2) without metastasis (M0). e Log CA
15-3 levels in T2 patients with lymph node involvement (N1 + N2)
without nodal involvement (N0). f Log CA 15-3 levels in T2 patients
with metastasis (M1 + M2) without metastasis (M0)
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from 20 to 50 % [34, 37, 38]. In metastatic patients, a combi-
nation of CA 15-3 with CEA and HER 2 increased the sensi-
tivity to 64 % [39], and a recent study claimed that the com-
bination of CEA, CA 15-3, and TK1 protein increased the
sensitivity to 90 % [25]. In the present study, we found posi-
tive correlations between TK1 activity and TK1 protein values
with the CA 15-3 values, especially in the case of T2 patients.
The combination of TK 210 ELISA and CA 15-3 biomarkers
increased the sensitivity from 0.61 and 0.63 respectively, of
each alone to 0.76 when the two marker were combined.
Thus, the results from this study strongly suggest that a com-
bination of TK 210 ELISA with CA 15-3 will be highly in-
formative as they apparently provide complementary informa-
tion. Further clinical evaluation of TK 210 ELISA in breast
cancer management, in larger case-control clinical studies
seems therefore highly motivated.
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